Subtype
Anorectal Neoplasm
CI-CAN-00001814Explore in graph →
Non-malignant504 active trials1 approved drugs6 evidence items
- NCIt
- C215222
Loading cancer entity…
Subtype
CI-CAN-00001814Explore in graph →
Clinical trials
2,046 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02698293 | PDT Plus Vitamin D3 for Anal Dysplasia | withdrawn | Phase 1 | 0 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 4, 2026 | clinicaltrials |
| NCT01097239 | Examining the Role of Transrectal High Intensity Focused Ultrasound (HIFU) in Rectal Pelvic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Imperial College LondonOTHER | 1 | Nov 20, 2020 | clinicaltrials |
| NCT01302613 |
| Altered Chemotherapy Sequencing During Neoadjuvant Therapy for Patients With Stage II or III Rectal Adenocarcinoma |
| withdrawn |
| Phase 1 / Phase 2 |
| 0 |
| University of Texas Southwestern Medical CenterOTHER |
| 1 |
| Aug 20, 2020 |
| clinicaltrials |
| NCT03007771 | Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia | withdrawn | Phase 1 | 0 | Washington University School of MedicineOTHER | 0 | Oct 6, 2017 | clinicaltrials |
| NCT02575508 | Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer | withdrawn | Phase 1 / Phase 2 | 0 | Roswell Park Cancer InstituteOTHER | 1 | May 20, 2016 | clinicaltrials |
| NCT00575640 | Hydralazine as a Demethylating Agent in Rectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | University of ArkansasOTHER | 0 | Mar 4, 2015 | clinicaltrials |
| NCT00503932 | Proton Therapy With Capecitabine for Rectal Cancer | withdrawn | Phase 1 / Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Mar 22, 2012 | clinicaltrials |
| NCT00780988 | Feasibility of Autologous Tumor Cell-TLR9 Agonist Vaccination for Metastatic Colorectal Cancer | withdrawn | Phase 1 | 0 | Stanford UniversityOTHER | 1 | Jan 24, 2012 | clinicaltrials |
Data updated 23 days agoSource updated Aug 4, 2026source: clinicaltrials